PRMT5 and systemic sclerosis: Our study here is the first to identify PRMT5 as a novel autoantibody target of the autoimmune response in patients with SSc based on large-scale proteomics with automated DEEP SEQ.22 Anti-PRMT5 antibodies are present in 31.11% of patients with SSc and absent in HCs.